A lipidated ring peptide has blocked SARS-CoV-2 fusion in a new way. The peptide, called S-880008, was reported by a team from Shionogi and Hokkaido University, led by Sanaki, Kawaguchi, Anraku and colleagues, in Nature Communications on 28 October 2026.
The work so far is structural and in animals. It has not been tested in people.
What S-880008 is
S-880008 is a macrocyclic peptide, meaning its amino acids are joined into a ring, with a lipid chain attached. The team found it using mRNA display, a laboratory method for screening very large libraries of peptides for ones that bind a chosen target.
A dual hold on the spike
The researchers then worked out how the peptide grips the virus spike, using cryo-EM. It holds the spike in two places at once. The ring parks where the receptor-binding domain (RBD) meets subdomain 1, while the lipid chain slips into the N-terminal domain of the neighbouring protomer, one of the spike's three units.
That double grip locks the spike in a shape with all three RBDs raised, called RBD 3-up. It also stops the protomers coming apart, and this blocks fusion, the step in which the virus merges with a host cell.
Across variants and in mice
The peptide worked across variants of SARS-CoV-2, including Omicron. Given into the nose of infected mice, it cut viral load and improved survival.
How early this is
These are animal and structural results. Whether the peptide would be safe and effective in people, and how it would be given, are questions for later studies.